Drug Profile
Atabecestat - Janssen Pharmaceuticals
Alternative Names: JNJ-54861911; RSC-385896Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Shionogi
- Developer Janssen Research & Development
- Class Amides; Antidementias; Small molecules; Thiazines
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 16 Jul 2019 Final efficacy and adverse events data from a phase II/III EARLY trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2019 (AAIC-2019)
- 28 Jun 2018 Janssen Research & Development completes a phase II trial in Alzheimer's disease (In adults, In the elderly) in Belgium, France, Germany, Netherlands, Spain and Sweden (PO) (NCT02406027)
- 04 Jun 2018 Chemical structure information added